ABTL 0812

Drug Profile

ABTL 0812

Alternative Names: ABTL-0812; ABTL0812 (lipid analog therapeutic molecule); LP-10218

Latest Information Update: 15 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lipopharma
  • Developer Ability Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Autophagy inhibitors; Autophagy stimulants; Gene expression inhibitors; MTORC1 protein inhibitors; MTORC2 protein inhibitors; Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Pancreatic cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Endometrial cancer; Lung cancer
  • Phase I Solid tumours
  • Preclinical Neuroblastoma; Pancreatic cancer

Most Recent Events

  • 13 Dec 2017 The US FDA approves IND application for ABTL 0812 inendometrial cancer and lung cancer
  • 05 Dec 2017 Ability Pharmaceuticals plans a phase I/II trial for Pancreatic cancer (First-line therapy, Late-stage disease, Combination therapy, Metastatic disease) (NCT03362892)
  • 05 Oct 2017 Preclinical trials in Neuroblastoma in Spain (PO) before October 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top